{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:20:21Z","timestamp":1789676421166,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Orthop Surg Traumatol"],"DOI":"10.1007\/s00590-024-04018-1","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:01:41Z","timestamp":1717570901000},"page":"2823-2833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-2008","authenticated-orcid":false,"given":"Shinji","family":"Tsukamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas F.","family":"Mavrogenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Masunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisaki","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Aso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanya","family":"Honoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Errani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"4018_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2:e192535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535","journal-title":"JAMA Netw Open"},{"key":"4018_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2023.100505","volume":"43","author":"GJ Joseph","year":"2023","unstructured":"Joseph GJ, Johnson DB, Johnson RW (2023) Immune checkpoint inhibitors in bone metastasis: clinical challenges, toxicities, and mechanisms. J Bone Oncol 43:100505. https:\/\/doi.org\/10.1016\/j.jbo.2023.100505","journal-title":"J Bone Oncol"},{"key":"4018_CR3","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00262-018-2239-4","volume":"67","author":"S Schmid","year":"2018","unstructured":"Schmid S, Diem S, Li Q et al (2018) Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother 67:1825\u20131832. https:\/\/doi.org\/10.1007\/s00262-018-2239-4","journal-title":"Cancer Immunol Immunother"},{"key":"4018_CR4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.6004\/jnccn.2020.7668","volume":"19","author":"A Qin","year":"2021","unstructured":"Qin A, Zhao S, Miah A et al (2021) Bone metastases, skeletal-related events, and survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. J Natl Compr Canc Netw 19:915\u2013921. https:\/\/doi.org\/10.6004\/jnccn.2020.7668","journal-title":"J Natl Compr Canc Netw"},{"key":"4018_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2217\/fon-2020-0587","volume":"17","author":"LM da Silva","year":"2021","unstructured":"da Silva LM, da Silva GT, Bergmann A et al (2021) Impact of different patterns of metastasis in non-small-cell lung cancer patients. Future Oncol 17:775\u2013782. https:\/\/doi.org\/10.2217\/fon-2020-0587","journal-title":"Future Oncol"},{"key":"4018_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","volume":"7","author":"L Landi","year":"2019","unstructured":"Landi L, D\u2019Inc\u00e0 F, Gelibter A et al (2019) Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer 7:316. https:\/\/doi.org\/10.1186\/s40425-019-0793-8","journal-title":"J Immunother Cancer"},{"key":"4018_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.critrevonc.2005.03.011","volume":"56","author":"G Selvaggi","year":"2005","unstructured":"Selvaggi G, Scagliotti GV (2005) Management of bone metastases in cancer: a review. Crit Rev Oncol Hematol 56:365\u2013378. https:\/\/doi.org\/10.1016\/j.critrevonc.2005.03.011","journal-title":"Crit Rev Oncol Hematol"},{"key":"4018_CR8","doi-asserted-by":"publisher","first-page":"230949902091598","DOI":"10.1177\/2309499020915989","volume":"28","author":"W Jiang","year":"2020","unstructured":"Jiang W, Rixiati Y, Zhao B et al (2020) Incidence, prevalence, and outcomes of systemic malignancy with bone metastases. J Orthop Surg 28:2309499020915989. https:\/\/doi.org\/10.1177\/2309499020915989","journal-title":"J Orthop Surg"},{"key":"4018_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.21037\/atm.2020.03.55","volume":"8","author":"J-F Huang","year":"2020","unstructured":"Huang J-F, Shen J, Li X et al (2020) Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med 8:482. https:\/\/doi.org\/10.21037\/atm.2020.03.55","journal-title":"Ann Transl Med"},{"key":"4018_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","volume":"48","author":"E Woodward","year":"2011","unstructured":"Woodward E, Jagdev S, McParland L et al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48:160\u2013166. https:\/\/doi.org\/10.1016\/j.bone.2010.09.008","journal-title":"Bone"},{"key":"4018_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/jso.22061","volume":"105","author":"AF Mavrogenis","year":"2012","unstructured":"Mavrogenis AF, Pala E, Romagnoli C et al (2012) Survival analysis of patients with femoral metastases. J Surg Oncol 105:135\u2013141. https:\/\/doi.org\/10.1002\/jso.22061","journal-title":"J Surg Oncol"},{"key":"4018_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.871675","volume":"12","author":"Y Asano","year":"2022","unstructured":"Asano Y, Yamamoto N, Demura S et al (2022) The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer. Front Oncol 12:871675. https:\/\/doi.org\/10.3389\/fonc.2022.871675","journal-title":"Front Oncol"},{"key":"4018_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4018_CR14","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","volume":"22","author":"T Hamaoka","year":"2004","unstructured":"Hamaoka T, Madewell JE, Podoloff DA et al (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942\u20132953. https:\/\/doi.org\/10.1200\/JCO.2004.08.181","journal-title":"J Clin Oncol"},{"key":"4018_CR15","doi-asserted-by":"crossref","unstructured":"Mirels H (1989) Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 256\u2013264","DOI":"10.1097\/00003086-198912000-00027"},{"key":"4018_CR16","doi-asserted-by":"publisher","first-page":"6832","DOI":"10.3390\/ijms23126832","volume":"23","author":"A Del Conte","year":"2022","unstructured":"Del Conte A, De Carlo E, Bertoli E et al (2022) Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): microenvironment and possible clinical implications. Int J Mol Sci 23:6832. https:\/\/doi.org\/10.3390\/ijms23126832","journal-title":"Int J Mol Sci"},{"key":"4018_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4018_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","volume":"66","author":"SY Kim","year":"2013","unstructured":"Kim SY, Park JE, Lee YJ et al (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 66:408\u2013414. https:\/\/doi.org\/10.1016\/j.jclinepi.2012.09.016","journal-title":"J Clin Epidemiol"},{"key":"4018_CR19","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.3390\/cancers14071735","volume":"14","author":"T Shimizu","year":"2022","unstructured":"Shimizu T, Miyake M, Nishimura N et al (2022) Organ-specific and mixed responses to pembrolizumab in patients with unresectable or metastatic urothelial carcinoma: a multicenter retrospective study. Cancers 14:1735. https:\/\/doi.org\/10.3390\/cancers14071735","journal-title":"Cancers"},{"key":"4018_CR20","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00432-022-04120-z","volume":"149","author":"A De Giglio","year":"2023","unstructured":"De Giglio A, Deiana C, Di Federico A (2023) Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients. J Cancer Res Clin Oncol 149:1835\u20131847. https:\/\/doi.org\/10.1007\/s00432-022-04120-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"4018_CR21","doi-asserted-by":"publisher","first-page":"12425","DOI":"10.1002\/cam4.5952","volume":"12","author":"Y Asano","year":"2023","unstructured":"Asano Y, Yamamoto N, Demura S et al (2023) Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis. Cancer Med 12:12425\u201312437. https:\/\/doi.org\/10.1002\/cam4.5952","journal-title":"Cancer Med"},{"key":"4018_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.697298","volume":"12","author":"A Bongiovanni","year":"2021","unstructured":"Bongiovanni A, Foca F, Menis J et al (2021) Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio. Front Immunol 12:697298. https:\/\/doi.org\/10.3389\/fimmu.2021.697298","journal-title":"Front Immunol"},{"key":"4018_CR23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.21873\/anticanres.14913","volume":"41","author":"T Negishi","year":"2021","unstructured":"Negishi T, Furubayashi N, Nakagawa T et al (2021) Site-specific response to nivolumab in renal cell carcinoma. Anticancer Res 41:1539\u20131545. https:\/\/doi.org\/10.21873\/anticanres.14913","journal-title":"Anticancer Res"},{"key":"4018_CR24","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.3892\/ol.2020.11856","volume":"20","author":"E Nakata","year":"2020","unstructured":"Nakata E, Sugihara S, Sugawara Y et al (2020) Early response of bone metastases can predict tumor response in patients with non-small-cell lung cancer with bone metastases in the treatment with nivolumab. Oncol Lett 20:2977\u20132986. https:\/\/doi.org\/10.3892\/ol.2020.11856","journal-title":"Oncol Lett"},{"key":"4018_CR25","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00262-019-02353-5","volume":"68","author":"Y Angela","year":"2019","unstructured":"Angela Y, Haferkamp S, Weishaupt C et al (2019) Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases. Cancer Immunol Immunother 68:1187\u20131194. https:\/\/doi.org\/10.1007\/s00262-019-02353-5","journal-title":"Cancer Immunol Immunother"},{"key":"4018_CR26","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2147\/OTT.S299724","volume":"14","author":"N Furubayashi","year":"2021","unstructured":"Furubayashi N, Negishi T, Sakamoto N et al (2021) Organ-specific tumor response to pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy. Onco Targets Ther 14:1981\u20131988. https:\/\/doi.org\/10.2147\/OTT.S299724","journal-title":"Onco Targets Ther"},{"key":"4018_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.5858\/arpa.2012-0287-RA","volume":"137","author":"K Raparia","year":"2013","unstructured":"Raparia K, Villa C, DeCamp MM et al (2013) Molecular profiling in non-small cell lung cancer: a step toward personalized medicine. Arch Pathol Lab Med 137:481\u2013491. https:\/\/doi.org\/10.5858\/arpa.2012-0287-RA","journal-title":"Arch Pathol Lab Med"},{"key":"4018_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jseint.2022.03.006","volume":"6","author":"KA Hoban","year":"2022","unstructured":"Hoban KA, Downie S, Adamson DJA et al (2022) Mirels\u2019 score for upper limb metastatic lesions: do we need a different cutoff for recommending prophylactic fixation? JSES Int 6:675\u2013681. https:\/\/doi.org\/10.1016\/j.jseint.2022.03.006","journal-title":"JSES Int"},{"key":"4018_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1302\/0301-620X.86B4.14703","volume":"86","author":"YM Van der Linden","year":"2004","unstructured":"Van der Linden YM, Dijkstra PDS, Kroon HM et al (2004) Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br 86:566\u2013573","journal-title":"J Bone Joint Surg Br"},{"key":"4018_CR30","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/jor.22887","volume":"33","author":"JR Goodheart","year":"2015","unstructured":"Goodheart JR, Cleary RJ, Damron TA, Mann KA (2015) Simulating activities of daily living with finite element analysis improves fracture prediction for patients with metastatic femoral lesions. J Orthop Res 33:1226\u20131234. https:\/\/doi.org\/10.1002\/jor.22887","journal-title":"J Orthop Res"},{"key":"4018_CR31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11999-015-4453-0","volume":"474","author":"TA Damron","year":"2016","unstructured":"Damron TA, Nazarian A, Entezari V et al (2016) CT-based structural rigidity analysis is more accurate than mirels scoring for fracture prediction in metastatic femoral lesions. Clin Orthop Relat Res 474:643\u2013651. https:\/\/doi.org\/10.1007\/s11999-015-4453-0","journal-title":"Clin Orthop Relat Res"},{"key":"4018_CR32","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1302\/0301-620X.102B5.BJJ-2019-1328.R2","volume":"102-B","author":"A Sternheim","year":"2020","unstructured":"Sternheim A, Traub F, Trabelsi N et al (2020) When and where do patients with bone metastases actually break their femurs? Bone Joint J 102-B:638\u2013645. https:\/\/doi.org\/10.1302\/0301-620X.102B5.BJJ-2019-1328.R2","journal-title":"Bone Joint J"},{"key":"4018_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.radonc.2019.10.007","volume":"144","author":"CWPG van der Wal","year":"2020","unstructured":"van der Wal CWPG, Eggermont F, Fiocco M et al (2020) Axial cortical involvement of metastatic lesions to identify impending femoral fractures; a clinical validation study. Radiother Oncol 144:59\u201364. https:\/\/doi.org\/10.1016\/j.radonc.2019.10.007","journal-title":"Radiother Oncol"},{"key":"4018_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0009-9260(87)80207-6","volume":"38","author":"EA Bellamy","year":"1987","unstructured":"Bellamy EA, Nicholas D, Ward M et al (1987) Comparison of computed tomography and conventional radiology in the assessment of treatment response of lytic bony metastases in patients with carcinoma of the breast. Clin Radiol 38:351\u2013355. https:\/\/doi.org\/10.1016\/s0009-9260(87)80207-6","journal-title":"Clin Radiol"},{"key":"4018_CR35","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.injury.2010.09.018","volume":"41","author":"P Ruggieri","year":"2010","unstructured":"Ruggieri P, Mavrogenis AF, Casadei R et al (2010) Protocol of surgical treatment of long bone pathological fractures. Injury 41:1161\u20131167. https:\/\/doi.org\/10.1016\/j.injury.2010.09.018","journal-title":"Injury"},{"key":"4018_CR36","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1302\/0301-620X.87B12.16629","volume":"87","author":"R Wedin","year":"2005","unstructured":"Wedin R, Bauer HCF (2005) Surgical treatment of skeletal metastatic lesions of the proximal femur: endoprosthesis or reconstruction nail? J Bone Joint Surg Br 87:1653\u20131657. https:\/\/doi.org\/10.1302\/0301-620X.87B12.16629","journal-title":"J Bone Joint Surg Br"},{"key":"4018_CR37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3109\/17453678108992157","volume":"52","author":"M Fidler","year":"1981","unstructured":"Fidler M (1981) Incidence of fracture through metastases in long bones. Acta Orthop Scand 52:623\u2013627. https:\/\/doi.org\/10.3109\/17453678108992157","journal-title":"Acta Orthop Scand"},{"key":"4018_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s0167-8140(03)00232-9","volume":"69","author":"YM van der Linden","year":"2003","unstructured":"van der Linden YM, Kroon HM, Dijkstra SPDS et al (2003) Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions: results from a randomised trial. Radiother Oncol 69:21\u201331. https:\/\/doi.org\/10.1016\/s0167-8140(03)00232-9","journal-title":"Radiother Oncol"},{"key":"4018_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115101","volume":"130","author":"F Eggermont","year":"2020","unstructured":"Eggermont F, van der Wal G, Westhoff P et al (2020) Patient-specific finite element computer models improve fracture risk assessments in cancer patients with femoral bone metastases compared to clinical guidelines. Bone 130:115101. https:\/\/doi.org\/10.1016\/j.bone.2019.115101","journal-title":"Bone"},{"key":"4018_CR40","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/CAD.0000000000000689","volume":"29","author":"F Comito","year":"2018","unstructured":"Comito F, Ambrosini V, Sperandi F et al (2018) Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma. Anticancer Drugs 29:1026\u20131029. https:\/\/doi.org\/10.1097\/CAD.0000000000000689","journal-title":"Anticancer Drugs"},{"key":"4018_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13256-021-02821-6","volume":"15","author":"S Ito","year":"2021","unstructured":"Ito S, Tachimori Y, Terado Y et al (2021) Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report. J Med Case Rep 15:237. https:\/\/doi.org\/10.1186\/s13256-021-02821-6","journal-title":"J Med Case Rep"},{"key":"4018_CR42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s13691-016-0256-8","volume":"5","author":"S-I Kageyama","year":"2016","unstructured":"Kageyama S-I, Yamaguchi S, Ito S et al (2016) A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis. Int Cancer Conf J 5:192\u2013196. https:\/\/doi.org\/10.1007\/s13691-016-0256-8","journal-title":"Int Cancer Conf J"},{"key":"4018_CR43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1128611","volume":"5","author":"K Lankes","year":"2016","unstructured":"Lankes K, Hundorfean G, Harrer T et al (2016) Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. Oncoimmunology 5:e1128611. https:\/\/doi.org\/10.1080\/2162402X.2015.1128611","journal-title":"Oncoimmunology"},{"key":"4018_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592609","volume":"10","author":"J Matull","year":"2020","unstructured":"Matull J, Livingstone E, Wetter A et al (2020) Durable Complete response in a melanoma patient with unknown primary, associated with sequential and severe multi-organ toxicity after a single dose of CTLA-4 plus PD-1 blockade: a case report. Front Oncol 10:592609. https:\/\/doi.org\/10.3389\/fonc.2020.592609","journal-title":"Front Oncol"},{"key":"4018_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s40425-018-0444-5","volume":"6","author":"LJC Oliveira","year":"2018","unstructured":"Oliveira LJC, Gongora ABL, Barbosa FG et al (2018) Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. J Immunother Cancer 6:130. https:\/\/doi.org\/10.1186\/s40425-018-0444-5","journal-title":"J Immunother Cancer"},{"key":"4018_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2023.102358","volume":"47","author":"K Kokura","year":"2023","unstructured":"Kokura K, Watanabe J, Takuma T et al (2023) A case of Avelumab response to multiple bone and lymph node metastases of plasmacytoid variant bladder cancer. Urol Case Rep 47:102358. https:\/\/doi.org\/10.1016\/j.eucr.2023.102358","journal-title":"Urol Case Rep"},{"key":"4018_CR47","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.936552","volume":"23","author":"A Laffi","year":"2022","unstructured":"Laffi A, Cozzi G, Spada F et al (2022) Metachronous testicular metastases from merkel cell carcinoma (MCC): a case report and literature review. Am J Case Rep 23:e936552. https:\/\/doi.org\/10.12659\/AJCR.936552","journal-title":"Am J Case Rep"},{"key":"4018_CR48","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/iju5.12504","volume":"5","author":"S Tamada","year":"2022","unstructured":"Tamada S, Ikarashi D, Tsuyukubo T et al (2022) Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: a report on two cases. IJU Case Rep 5:438\u2013441. https:\/\/doi.org\/10.1002\/iju5.12504","journal-title":"IJU Case Rep"},{"key":"4018_CR49","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.21873\/anticanres.14412","volume":"40","author":"M Yano","year":"2020","unstructured":"Yano M, Aso S, Sato M et al (2020) Pembrolizumab and radiotherapy for platinum-refractory recurrent uterine carcinosarcoma with an abscopal effect: a case report. Anticancer Res 40:4131\u20134135. https:\/\/doi.org\/10.21873\/anticanres.14412","journal-title":"Anticancer Res"},{"key":"4018_CR50","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1007\/s00262-022-03180-x","volume":"71","author":"E Gefard-Gontier","year":"2022","unstructured":"Gefard-Gontier E, Markich R, Zysman M et al (2022) Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors. Cancer Immunol Immunother 71:2609\u20132618. https:\/\/doi.org\/10.1007\/s00262-022-03180-x","journal-title":"Cancer Immunol Immunother"},{"key":"4018_CR51","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/JTO.0b013e3181d3e47e","volume":"5","author":"JSW Lind","year":"2010","unstructured":"Lind JSW, Postmus PE, Smit EF (2010) Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report. J Thorac Oncol 5:554\u2013557. https:\/\/doi.org\/10.1097\/JTO.0b013e3181d3e47e","journal-title":"J Thorac Oncol"},{"key":"4018_CR52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","volume":"6","author":"RE Coleman","year":"2020","unstructured":"Coleman RE, Croucher PI, Padhani AR et al (2020) Bone metastases. Nat Rev Dis Primers 6:83. https:\/\/doi.org\/10.1038\/s41572-020-00216-3","journal-title":"Nat Rev Dis Primers"},{"key":"4018_CR53","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00256-011-1253-9","volume":"41","author":"Y Yamashita","year":"2012","unstructured":"Yamashita Y, Aoki T, Hanagiri T et al (2012) Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response. Skeletal Radiol 41:409\u2013414. https:\/\/doi.org\/10.1007\/s00256-011-1253-9","journal-title":"Skeletal Radiol"},{"key":"4018_CR54","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/CORR.0000000000000803","volume":"478","author":"TC Philipp","year":"2020","unstructured":"Philipp TC, Mikula JD, Doung Y-C, Gundle KR (2020) Is there an association between prophylactic femur stabilization and survival in patients with metastatic bone disease? Clin Orthop Relat Res 478:540\u2013546. https:\/\/doi.org\/10.1097\/CORR.0000000000000803","journal-title":"Clin Orthop Relat Res"},{"key":"4018_CR55","doi-asserted-by":"publisher","DOI":"10.1097\/01.blo.0000093849.72468.82","author":"WG Ward","year":"2003","unstructured":"Ward WG, Holsenbeck S, Dorey FJ et al (2003) Metastatic disease of the femur: surgical treatment. Clin Orthop Relat Res. https:\/\/doi.org\/10.1097\/01.blo.0000093849.72468.82","journal-title":"Clin Orthop Relat Res"},{"key":"4018_CR56","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1097\/CORR.0000000000000489","volume":"476","author":"RP McLynn","year":"2018","unstructured":"McLynn RP, Ondeck NT, Grauer JN, Lindskog DM (2018) What is the adverse event profile after prophylactic treatment of femoral shaft or distal femur metastases? Clin Orthop Relat Res 476:2381\u20132388. https:\/\/doi.org\/10.1097\/CORR.0000000000000489","journal-title":"Clin Orthop Relat Res"},{"key":"4018_CR57","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2106\/JBJS.16.00023","volume":"99","author":"A Aneja","year":"2017","unstructured":"Aneja A, Jiang JJ, Cohen-Rosenblum A et al (2017) Thromboembolic disease in patients with metastatic femoral lesions: a comparison between prophylactic fixation and fracture fixation. J Bone Joint Surg Am 99:315\u2013323. https:\/\/doi.org\/10.2106\/JBJS.16.00023","journal-title":"J Bone Joint Surg Am"},{"key":"4018_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03300-8","author":"L Liu","year":"2023","unstructured":"Liu L, Shi Z, Qiu X (2023) Impact of bone metastasis on the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Clin Transl Oncol. https:\/\/doi.org\/10.1007\/s12094-023-03300-8","journal-title":"Clin Transl Oncol"},{"key":"4018_CR59","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.3390\/curroncol28050290","volume":"28","author":"S Tsukamoto","year":"2021","unstructured":"Tsukamoto S, Kido A, Tanaka Y et al (2021) Current overview of treatment for metastatic bone disease. Curr Oncol 28:3347\u20133372. https:\/\/doi.org\/10.3390\/curroncol28050290","journal-title":"Curr Oncol"}],"container-title":["European Journal of Orthopaedic Surgery & Traumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-024-04018-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00590-024-04018-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-024-04018-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T21:02:48Z","timestamp":1725570168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00590-024-04018-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["4018"],"URL":"https:\/\/doi.org\/10.1007\/s00590-024-04018-1","relation":{},"ISSN":["1432-1068"],"issn-type":[{"value":"1432-1068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"31 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}